Peter W Eide
Overview
Explore the profile of Peter W Eide including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
828
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bruun J, Eide P, Bergsland C, Bruck O, Svindland A, Arjama M, et al.
Mol Oncol
. 2021 Dec;
16(12):2312-2329.
PMID: 34890102
Cell-cell and cell-matrix adhesion proteins that have been implicated in colorectal epithelial integrity and epithelial-to-mesenchymal transition could be robust prognostic and potential predictive biomarkers for standard and novel therapies. We...
2.
Kryeziu K, Moosavi S, Bergsland C, Guren M, Eide P, Totland M, et al.
J Transl Med
. 2021 Sep;
19(1):384.
PMID: 34496878
Tumor heterogeneity is a primary cause of treatment failure. However, changes in drug sensitivity over time are not well mapped in cancer. Patient-derived organoids (PDOs) may predict clinical drug responses...
3.
Sveen A, Johannessen B, Eilertsen I, Rosok B, Gulla M, Eide P, et al.
Genome Med
. 2021 Sep;
13(1):142.
PMID: 34470667
Background: Colorectal cancer is the 2nd leading cause of cancer-related deaths with few patients benefiting from biomarker-guided therapy. Mutation expression is essential for accurate interpretation of mutations as biomarkers, but...
4.
Moosavi S, Eide P, Eilertsen I, Brunsell T, Berg K, Rosok B, et al.
Genome Med
. 2021 Sep;
13(1):143.
PMID: 34470666
Background: Gene expression-based subtyping has the potential to form a new paradigm for stratified treatment of colorectal cancer. However, current frameworks are based on the transcriptomic profiles of primary tumors,...
5.
Eide P, Moosavi S, Eilertsen I, Brunsell T, Langerud J, Berg K, et al.
NPJ Genom Med
. 2021 Jul;
6(1):59.
PMID: 34262039
Gene expression-based subtypes of colorectal cancer have clinical relevance, but the representativeness of primary tumors and the consensus molecular subtypes (CMS) for metastatic cancers is not well known. We investigated...
6.
Smeby J, Kryeziu K, Berg K, Eilertsen I, Eide P, Johannessen B, et al.
EBioMedicine
. 2020 Aug;
59:102923.
PMID: 32799124
Background: PARP inhibitors are active in various tumour types beyond BRCA-mutant cancers, but their activity and molecular correlates in colorectal cancer (CRC) are not well studied. Methods: Mutations and genome-wide...
7.
Bruun J, Kryeziu K, Eide P, Moosavi S, Eilertsen I, Langerud J, et al.
Clin Cancer Res
. 2020 Apr;
26(15):4107-4119.
PMID: 32299813
Purpose: Molecular tumor heterogeneity may have important implications for the efficacy of targeted therapies in metastatic cancers. Inter-metastatic heterogeneity of sensitivity to anticancer agents has not been well explored in...
8.
Smeby J, Sveen A, Bergsland C, Eilertsen I, Danielsen S, Eide P, et al.
ESMO Open
. 2019 Jul;
4(3):e000523.
PMID: 31321083
Background: Accumulating evidence suggests immunomodulatory and context-dependent effects of mutations in cancer. We performed an exploratory analysis of the transcriptional, immunobiological and prognostic associations of mutations within the gene expression-based...
9.
Smeby J, Sveen A, Eilertsen I, Danielsen S, Hoff A, Eide P, et al.
Oncogenesis
. 2019 May;
8(6):35.
PMID: 31092812
TP53 mutations are common in colorectal cancer (CRC). Most TP53 sequencing studies have been restricted to coding regions, but recent studies have revealed that splice mutations can generate transcript variants...
10.
Eide P, Eilertsen I, Sveen A, Lothe R
Int J Cancer
. 2018 Nov;
144(11):2843-2853.
PMID: 30447009
Elevated miR-31 expression is associated with poor outcome in colorectal cancer (CRC). Whether the prognostic information is independent of known molecular subgroups and gene expression-based consensus molecular subtypes (CMS) is...